Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.

Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A.

Clin Cancer Res. 2019 Aug 1. doi: 10.1158/1078-0432.CCR-19-0138. [Epub ahead of print]

PMID:
31371343
2.

Targeting Apoptosis: A New Paradigm for the Treatment of Estrogen Receptor-Positive Breast Cancer.

Drago JZ, Chandarlapaty S, Jhaveri K.

Cancer Discov. 2019 Mar;9(3):323-325. doi: 10.1158/2159-8290.CD-19-0050.

PMID:
30824486
3.

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.

Drago JZ, Lawrence D, Livingstone E, Zimmer L, Chen T, Giobbie-Hurder A, Amann VC, Mangana J, Siano M, Zippelius A, Dummer R, Goldinger SM, Sullivan RJ.

Melanoma Res. 2019 Feb;29(1):65-69. doi: 10.1097/CMR.0000000000000527.

PMID:
30376465
4.

The Harm in Kratom.

Drago JZ, Lane B, Kochav J, Chabner B.

Oncologist. 2017 Jul 24. pii: theoncologist.2017-0279. doi: 10.1634/theoncologist.2017-0279. [Epub ahead of print] No abstract available.

Supplemental Content

Loading ...
Support Center